Target Information

Target General Information

Target ID

T47094 (Former ID: TTDS00194)

Target Name

Substance-P receptor (TACR1)

Synonyms

Tachykinin receptor 1; Tachykinin neurokinin 1 receptor; Tachykinin 1 receptor; TACR1; Substance P receptor; SPR; Neurokinin 1 receptor; NK-1R; NK-1 receptor

Click to Show/Hide

Gene Name

TACR1

Target Type

Successful target

[1]

Disease

[+] 2 Target-related Diseases

Depression [ICD-11: 6A70-6A7Z]

Nausea/vomiting [ICD-11: MD90]

Function

This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K.

Click to Show/Hide

BioChemical Class

GPCR rhodopsin

UniProt ID

NK1R_HUMAN

Sequence

MDNVLPVDSDLSPNISTNTSEPNQFVQPAWQIVLWAAAYTVIVVTSVVGNVVVMWIILAH
KRMRTVTNYFLVNLAFAEASMAAFNTVVNFTYAVHNEWYYGLFYCKFHNFFPIAAVFASI
YSMTAVAFDRYMAIIHPLQPRLSATATKVVICVIWVLALLLAFPQGYYSTTETMPSRVVC
MIEWPEHPNKIYEKVYHICVTVLIYFLPLLVIGYAYTVVGITLWASEIPGDSSDRYHEQV
SAKRKVVKMMIVVVCTFAICWLPFHIFFLLPYINPDLYLKKFIQQVYLAIMWLAMSSTMY
NPIIYCCLNDRFRLGFKHAFRCCPFISAGDYEGLEMKSTRYLQTQGSVYKVSRLETTIST
VVGAHEEEPEDGPKATPSSLDLTSNCSSRSDSKTMTESFSFSSNVLS

Click to Show/Hide

3D Structure

Click to Show 3D Structure of This Target

PDB

HIT2.0 ID

T88A0X

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 4 Approved Drugs

Aprepitant

Drug Info

Approved

Depression

[2], [3]

Palonosetron + fosnetupitant

Drug Info

Approved

Chemotherapy-induced nausea

[4]

Rolapitant

Drug Info

Approved

Chemotherapy-induced nausea

[5], [6]

Selegiline

Drug Info

Approved

Major depressive disorder

[7], [8]

Clinical Trial Drug(s)

[+] 17 Clinical Trial Drugs

LY-686017

Drug Info

Phase 3

Atopic dermatitis

[10]

Netupitant

Drug Info

Phase 3

Chemotherapy-induced nausea

[11], [12]

Serlopitant

Drug Info

Phase 3

Prurigo nodularis

[10]

CP-122721

Drug Info

Phase 2

Major depressive disorder

[14]

DAPITANT

Drug Info

Phase 2

Pain

[15]

FR139317

Drug Info

Phase 2

Hypertension

[16], [17]

GW 597599

Drug Info

Phase 2

Mood disorder

[18]

LANEPITANT

Drug Info

Phase 2

Pain

[19], [20]

LY-2590443

Drug Info

Phase 2

Migraine

[21]

Orvepitant

Drug Info

Phase 2

Anxiety disorder

[22]

SCH-900978

Drug Info

Phase 2

Cough

[23]

SSR240600

Drug Info

Phase 2

Urinary incontinence

[24]

TKA-731

Drug Info

Phase 2

Pain

[25]

VOFOPITANT HYDROCHLORIDE

Drug Info

Phase 2

Vomiting

[26], [27]

CJ-12255

Drug Info

Phase 1

Eczema

[28]

Figopitant

Drug Info

Phase 1

Diabetic complication

[29]

GSK1144814

Drug Info

Phase 1

Schizophrenia

[30]

Discontinued Drug(s)

[+] 22 Discontinued Drugs

Casopitant

Drug Info

Withdrawn from market

Chemotherapy-induced nausea

[31], [32]

BL-1832

Drug Info

Discontinued in Phase 3

Pain

[33]

L-759274

Drug Info

Discontinued in Phase 3

Depression

[32]

CGP-49823

Drug Info

Discontinued in Phase 2

Pain

[36]

CS-003

Drug Info

Discontinued in Phase 2

Chronic obstructive pulmonary disease

[37]

DNK-333

Drug Info

Discontinued in Phase 2

Irritable bowel syndrome

[37]

Ezlopitant

Drug Info

Discontinued in Phase 2

Irritable bowel syndrome

[38], [39]

FK-224

Drug Info

Discontinued in Phase 2

Asthma

[40], [41]

FK-888

Drug Info

Discontinued in Phase 2

Migraine

[42], [43]

GSK 679769

Drug Info

Discontinued in Phase 2

Major depressive disorder

[39]

TA-5538

Drug Info

Discontinued in Phase 2

Overactive bladder

[44]

TAK-637

Drug Info

Discontinued in Phase 2

Depression

[32]

SDZ-NKT-343

Drug Info

Discontinued in Phase 1

Pain

[46]

SLV-323

Drug Info

Discontinued in Phase 1

Gastric motility disorder

[39]

FK-355

Drug Info

Terminated

Asthma

[47]

FR-113680

Drug Info

Terminated

Asthma

[48]

GR-82334

Drug Info

Terminated

Vomiting

[49]

L-741671

Drug Info

Terminated

Vomiting

[50]

MEN-11149

Drug Info

Terminated

Asthma

[51]

MEN-11467

Drug Info

Terminated

Respiratory tract inflammation

[52]

RP-67580

Drug Info

Terminated

Pain

[53], [54]

WIN-64821

Drug Info

Terminated

Asthma

[55]

Mode of Action

[+] 4 Modes of Action

Antagonist

[+] 48 Antagonist drugs

Aprepitant

Drug Info

[1]

Palonosetron + fosnetupitant

Drug Info

[4]

Rolapitant

Drug Info

[56]

Selegiline

Drug Info

[57]

LY-686017

Drug Info

[58]

Netupitant

Drug Info

[56]

Serlopitant

Drug Info

[10]

CP-122721

Drug Info

[59]

DAPITANT

Drug Info

[2], [60]

FR139317

Drug Info

[57]

GW 597599

Drug Info

[61]

LANEPITANT

Drug Info

[2], [62]

LY-2590443

Drug Info

[63]

Orvepitant

Drug Info

[57]

SCH-900978

Drug Info

[64]

SSR240600

Drug Info

[65]

TKA-731

Drug Info

[25]

VOFOPITANT HYDROCHLORIDE

Drug Info

[2], [66]

CJ-12255

Drug Info

[2], [67]

Figopitant

Drug Info

[68]

Casopitant

Drug Info

[32]

BL-1832

Drug Info

[70]

L-759274

Drug Info

[32]

CGP-49823

Drug Info

[71]

CS-003

Drug Info

[37]

Ezlopitant

Drug Info

[39], [73]

FK-888

Drug Info

[77]

GSK 679769

Drug Info

[39]

TA-5538

Drug Info

[78]

TAK-637

Drug Info

[32]

SDZ-NKT-343

Drug Info

[79]

CI-1021

Drug Info

[80]

FK-355

Drug Info

[75]

GR-82334

Drug Info

[83]

MEN-11149

Drug Info

[87]

MEN-11467

Drug Info

[88]

RP-67580

Drug Info

[89]

WIN-64821

Drug Info

[90]

befetupitant

Drug Info

[96]

CP-100263

Drug Info

[39]

CP-99,994

Drug Info

[80]

L-703,606

Drug Info

[98]

R116031

Drug Info

[103]

SCH 206272

Drug Info

[104]

spantide II

Drug Info

[106]

T2328

Drug Info

[108]

[125I]L703,606

Drug Info

[112]

[18F]SPA-RQ

Drug Info

[63]

Modulator

[+] 8 Modulator drugs

GSK1144814

Drug Info

[69]

DNK-333

Drug Info

[72]

FK-224

Drug Info

[74], [75], [76]

SLV-323

Drug Info

[39]

EU-C-001

Drug Info

[63]

WIN-64745

Drug Info

[110]

WIN-66306

Drug Info

[111]

WIN-68577

Drug Info

[111]

Inhibitor

[+] 43 Inhibitor drugs

CP-96345

Drug Info

[81]

FR-113680

Drug Info

[82]

L-732138

Drug Info

[84]

L-733060

Drug Info

[85]

L-741671

Drug Info

[86]

(D)-Phe-(D)-Phe-NH2

Drug Info

[91]

(D)-Phe-(L)-Phe-NH2

Drug Info

[91]

(L)-Phe-(D)-Phe-NH2

Drug Info

[91]

2-Phenyl-3-(1-phenyl-ethoxy)-piperidine

Drug Info

[85]

3,6-Diphenyl-1-oxa-7-aza-spiro[4.5]decane

Drug Info

[92]

3-Benzyloxy-2-phenyl-piperidine

Drug Info

[85]

4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one

Drug Info

[93]

7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (3,5-BIS-TRIFLUOROMETHYL-BENZYL)-METHYL-AMIDE (STRUCTURAL MIX)

Drug Info

[94]

7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(S)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX)

Drug Info

[94]

Ac-Phe-Phe-NH2

Drug Info

[91]

Arg-Pro-Lys-Pro-Ala-Gln-Phe-Phe-Gly-Leu-Met-NH2

Drug Info

[95]

Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2

Drug Info

[95]

Arg-Pro-Lys-Pro-Gln-Ser-Phe-Phe-Gly-Leu-Met-NH2

Drug Info

[95]

ENDOMORPHIN 2

Drug Info

[91]

H-Ala-Pro-Phe-Phe-NH2

Drug Info

[91]

H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH

Drug Info

[91]

H-Leu-Phe-NH2

Drug Info

[91]

H-Phe-NH2

Drug Info

[91]

H-Pro-Phe-Phe-NH2

Drug Info

[91]

H-Tyr(OMe)-Phe(2-Me)-NH2

Drug Info

[91]

H-Tyr-Ala-Phe-Phe-NH2

Drug Info

[91]

H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2

Drug Info

[97]

H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2

Drug Info

[97]

H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl

Drug Info

[97]

H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2

Drug Info

[97]

H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl

Drug Info

[97]

H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl

Drug Info

[97]

H-Tyr-Pro-Phe-Ala-NH2

Drug Info

[91]

H-Tyr-Pro-Phe-Phe-OH

Drug Info

[91]

L-708568

Drug Info

[99]

L-736281

Drug Info

[86]

MDL-28163

Drug Info

[100]

Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2

Drug Info

[95]

R-226161

Drug Info

[102]

SP-SAP

Drug Info

[63]

Substance P

Drug Info

[107]

Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl

Drug Info

[109]

[Sar9,Met(O2)11]-SP

Drug Info

[113]

Agonist

[+] 5 Agonist drugs

Homspera

Drug Info

[63]

kassinin

Drug Info

[98]

neurokinin A

Drug Info

[101]

physalaemin

Drug Info

[98]

Septide

Drug Info

[105]

Cell-based Target Expression Variations

Top

Cell-based Target Expression Variations

Cell-based Target Expression Variations Info

Drug Binding Sites of Target

Top

Ligand Name: Cholesterol

Ligand Info

Structure Description

Human Neurokinin 1 receptor (NK1R) substance P Gq chimera (mGsqi) complex

PDB:7P00

Method

Electron microscopy

Resolution

2.71 Å

Mutation

Yes

[114]

PDB Sequence

PNQFVQPAWQ

³¹

IVLWAAAYTV

⁴¹

IVVTSVVGNV

⁵¹

VVMWIILAHK

⁶¹

RMRTVTNYFL

⁷¹

VNLAFAEASM

⁸¹

AAFNTVVNFT

⁹¹

YAVHNEWYYG

¹⁰¹

LFYCKFHNFF

¹¹¹

PIAAVFASIY

¹²¹

SMTAVAFDRY

¹³¹

MAIIHPLQPR

¹⁴¹

LSATATKVVI

¹⁵¹

CVIWVLALLL

¹⁶¹

AFPQGYYSTT

¹⁷¹

ETMPSRVVCM

¹⁸¹

IEWPEHPNKI

¹⁹¹

YEKVYHICVT

²⁰¹

VLIYFLPLLV

²¹¹

IGYAYTVVGI

²²¹

TLWAYHEQVS

²⁴¹

AKRKVVKMMI

²⁵¹

VVVCTFAICW

²⁶¹

LPFHIFFLLP

²⁷¹

YINPDLYLKK

²⁸¹

FIQQVYLAIM

²⁹¹

WLAMSSTMYN

³⁰¹

PIIYCCLNDR

³¹¹

FRLGFKHA

Residue

Distance (Å)

LEU58

3.643

ARG64

3.280

TYR69

3.403

VAL72

3.875

ASN73

3.582

PHE76

3.682

Residue

Distance (Å)

PHE111

3.929

LYS148

4.003

ILE151

3.815

TRP155

3.575

LEU159

4.011

Click to View More Binding Site Information of This Target with Different Ligands

Different Human System Profiles of Target	Top
Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target. A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020). Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function. Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006). Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database. The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017). Human Similarity Proteins Human Pathway Affiliation Biological Network Descriptors

Different Human System Profiles of Target

Top

Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.

A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020).

Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.

Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006).

Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.

The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017).

Human Similarity Proteins

Human Pathway Affiliation

Biological Network Descriptors

Protein Name	Pfam ID	Percentage of Identity (%)	E value
Olfactory receptor 5K1 (OR5K1)	PF13853	27.344 (35/128)	1.38E-07
Olfactory receptor 5K2 (OR5K2)	PF13853	27.481 (36/131)	2.65E-07
Olfactory receptor 11H2 (OR11H2)	PF13853	22.590 (75/332)	2.84E-07
Olfactory receptor 10Q1 (OR10Q1)	PF13853	26.772 (34/127)	2.94E-07
Olfactory receptor 5M11 (OR5M11)	PF13853	25.694 (37/144)	2.66E-06
Olfactory receptor 2A14 (OR2A14)	PF13853	26.174 (39/149)	3.02E-06
Olfactory receptor 1J1 (OR1J1)	PF13853	28.467 (39/137)	3.10E-06
Olfactory receptor 5M3 (OR5M3)	PF13853	29.861 (43/144)	3.39E-06
Olfactory receptor 14J1 (OR14J1)	PF13853	23.016 (29/126)	3.57E-06
Olfactory receptor 8A1 (OR8A1)	PF13853	32.000 (32/100)	5.47E-06
Olfactory receptor 5I1 (OR5I1)	PF13853	29.565 (34/115)	9.39E-06
Olfactory receptor 11H1 (OR11H1)	PF13853	22.601 (73/323)	1.00E-05
Olfactory receptor 6C70 (OR6C70)	PF13853	23.000 (69/300)	1.67E-05
Olfactory receptor 6C75 (OR6C75)	PF13853	27.273 (39/143)	2.22E-05
Putative olfactory receptor 14L1 (OR14L1P)	PF13853	23.214 (26/112)	2.50E-05
Olfactory receptor 4D1 (OR4D1)	PF13853	22.483 (67/298)	2.66E-05
Olfactory receptor 13C4 (OR13C4)	PF13853	25.157 (80/318)	2.75E-05
Olfactory receptor 4K1 (OR4K1)	PF13853	28.378 (42/148)	3.02E-05
Olfactory receptor 8B3 (OR8B3)	PF13853	29.268 (36/123)	3.38E-05
Olfactory receptor 6C3 (OR6C3)	PF13853	23.344 (74/317)	4.39E-05
Olfactory receptor 5B17 (OR5B17)	PF13853	27.083 (39/144)	4.55E-05
Olfactory receptor 11H12 (OR11H12)	PF13853	22.840 (74/324)	4.80E-05
Olfactory receptor 14A16 (OR14A16)	PF13853	27.273 (30/110)	4.90E-05
Olfactory receptor 2A2 (OR2A2)	PF13853	26.316 (30/114)	5.08E-05
Olfactory receptor 1D2 (OR1D2)	PF13853	28.387 (44/155)	5.22E-05
Olfactory receptor 2A5 (OR2A5)	PF13853	25.926 (28/108)	5.89E-05
Olfactory receptor 6C68 (OR6C68)	PF13853	25.000 (37/148)	6.40E-05
Olfactory receptor 8D4 (OR8D4)	PF13853	28.906 (37/128)	6.68E-05
Olfactory receptor 2T34 (OR2T34)	PF13853	18.605 (40/215)	6.82E-05
Olfactory receptor 11H4 (OR11H4)	PF13853	26.812 (37/138)	7.85E-05
Olfactory receptor 5K4 (OR5K4)	PF13853	25.893 (29/112)	7.93E-05
Olfactory receptor 2T3 (OR2T3)	PF13853	18.605 (40/215)	8.15E-05
Olfactory receptor 5AL1 (OR5AL1)	PF13853	30.357 (34/112)	9.94E-05
Olfactory receptor 5H14 (OR5H14)	PF13853	27.679 (31/112)	1.04E-04
Olfactory receptor 11H7 (OR11H7)	PF13853	21.212 (70/330)	1.14E-04
Olfactory receptor 6C2 (OR6C2)	PF13853	28.082 (41/146)	1.69E-04
Olfactory receptor 6S1 (OR6S1)	PF13853	25.362 (35/138)	1.72E-04
Olfactory receptor 14I1 (OR14I1)	PF13853	28.099 (34/121)	1.79E-04
Olfactory receptor 6C1 (OR6C1)	PF13853	23.718 (37/156)	1.85E-04
Olfactory receptor 5H15 (OR5H15)	PF13853	30.088 (34/113)	2.02E-04
Olfactory receptor 1J2 (OR1J2)	PF13853	26.923 (35/130)	2.38E-04
Olfactory receptor 4E1 (OR4E1)	PF13853	24.348 (28/115)	2.48E-04
Olfactory receptor 8B2 (OR8B2)	PF13853	29.268 (36/123)	3.05E-04
Olfactory receptor 9G1 (OR9G1)	PF13853	26.923 (35/130)	3.14E-04
Olfactory receptor 5M1 (OR5M1)	PF13853	24.138 (35/145)	3.23E-04
Olfactory receptor 4K17 (OR4K17)	PF13853	27.407 (37/135)	3.53E-04
Olfactory receptor 5M9 (OR5M9)	PF13853	26.357 (34/129)	3.71E-04
Olfactory receptor 7A5 (OR7A5)	PF13853	24.000 (30/125)	3.90E-04
Olfactory receptor 1D4 (OR1D4)	PF13853	29.252 (43/147)	3.92E-04
Olfactory receptor 5H1 (OR5H1)	PF13853	27.679 (31/112)	3.98E-04
Olfactory receptor 8D2 (OR8D2)	PF13853	29.365 (37/126)	4.40E-04
Olfactory receptor 7G2 (OR7G2)	PF13853	25.000 (31/124)	4.93E-04
Olfactory receptor 11H6 (OR11H6)	PF13853	26.496 (31/117)	5.76E-04
Olfactory receptor 6C4 (OR6C4)	PF13853	23.256 (30/129)	5.92E-04
Olfactory receptor 5A1 (OR5A1)	PF13853	26.154 (34/130)	6.07E-04
Putative olfactory receptor 1F12P (OR1F12P)	PF13853	25.806 (40/155)	6.11E-04
Olfactory receptor 2K2 (OR2K2)	PF13853	25.217 (29/115)	7.33E-04
Olfactory receptor 1N1 (OR1N1)	PF13853	24.832 (37/149)	7.37E-04
Olfactory receptor 6B1 (OR6B1)	PF13853	26.446 (32/121)	7.50E-04
Olfactory receptor 10W1 (OR10W1)	PF13853	31.250 (35/112)	8.81E-04
Olfactory receptor 1G1 (OR1G1)	PF13853	24.528 (26/106)	1.00E-03
Olfactory receptor 8B8 (OR8B8)	PF13853	30.769 (40/130)	1.00E-03
Olfactory receptor 2AJ1 (OR2AJ1)	PF13853	23.264 (67/288)	1.00E-03
Olfactory receptor 4K3 (OR4K3)	PF13853	23.308 (31/133)	1.00E-03
Olfactory receptor 5B12 (OR5B12)	PF13853	26.897 (39/145)	1.00E-03
Olfactory receptor 8B12 (OR8B12)	PF13853	26.282 (41/156)	1.00E-03
Olfactory receptor 4K2 (OR4K2)	PF13853	21.118 (34/161)	1.00E-03
Olfactory receptor 1L1 (OR1L1)	PF13853	25.954 (34/131)	1.00E-03
Olfactory receptor 1L4 (OR1L4)	PF13853	29.412 (35/119)	1.00E-03
Olfactory receptor 2M5 (OR2M5)	PF13853	23.404 (55/235)	1.00E-03
Olfactory receptor 6V1 (OR6V1)	PF13853	23.077 (30/130)	1.00E-03
Olfactory receptor 9K2 (OR9K2)	PF13853	23.913 (33/138)	1.00E-03
Olfactory receptor 5M10 (OR5M10)	PF13853	25.862 (30/116)	2.00E-03
Olfactory receptor 2A12 (OR2A12)	PF13853	25.000 (30/120)	2.00E-03
Olfactory receptor 5M8 (OR5M8)	PF13853	28.030 (37/132)	2.00E-03
Olfactory receptor 10A3 (OR10A3)	PF13853	25.893 (29/112)	2.00E-03
Olfactory receptor 5D14 (OR5D14)	PF13853	27.193 (31/114)	2.00E-03
Olfactory receptor 1D5 (OR1D5)	PF13853	28.571 (42/147)	2.00E-03
Olfactory receptor 5B2 (OR5B2)	PF13853	25.000 (34/136)	2.00E-03
Olfactory receptor 51F1 (OR51F1)	PF13853	25.472 (27/106)	2.00E-03
Olfactory receptor 5AR1 (OR5AR1)	PF13853	24.427 (32/131)	2.00E-03
Olfactory receptor 2T2 (OR2T2)	PF13853	21.525 (48/223)	2.00E-03
Olfactory receptor 14A2 (OR14A2)	PF13853	24.161 (36/149)	2.00E-03
Olfactory receptor 5B21 (OR5B21)	PF13853	26.812 (37/138)	2.00E-03
Putative olfactory receptor 10J6 (OR10J6P)	PF13853	23.171 (38/164)	2.00E-03
Olfactory receptor 5AS1 (OR5AS1)	PF13853	25.150 (42/167)	2.00E-03
Olfactory receptor 4A15 (OR4A15)	PF13853	23.704 (32/135)	2.00E-03
Olfactory receptor 6C74 (OR6C74)	PF13853	23.077 (33/143)	3.00E-03
Olfactory receptor 3A1 (OR3A1)	PF13853	25.000 (32/128)	3.00E-03
Olfactory receptor 9G4 (OR9G4)	PF13853	23.853 (26/109)	3.00E-03
Olfactory receptor 5K3 (OR5K3)	PF13853	24.779 (28/113)	3.00E-03
Olfactory receptor 7A10 (OR7A10)	PF13853	20.755 (44/212)	3.00E-03
Olfactory receptor 1L6 (OR1L6)	PF13853	29.412 (35/119)	4.00E-03
Olfactory receptor 8I2 (OR8I2)	PF13853	26.087 (30/115)	4.00E-03
Olfactory receptor 4C13 (OR4C13)	PF13853	25.424 (30/118)	4.00E-03
Olfactory receptor 7D4 (OR7D4)	PF13853	24.060 (32/133)	4.00E-03
Olfactory receptor 7C2 (OR7C2)	PF13853	26.056 (37/142)	5.00E-03
Olfactory receptor 7A17 (OR7A17)	PF13853	24.260 (41/169)	5.00E-03
Olfactory receptor 4S1 (OR4S1)	PF13853	30.769 (32/104)	5.00E-03
Olfactory receptor 6N1 (OR6N1)	PF13853	24.468 (23/94)	5.00E-03
Click to Show/Hide the Information of Human Similarity Proteins

KEGG Pathway	Pathway ID	Affiliated Target
Calcium signaling pathway	hsa04020	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
Neuroactive ligand-receptor interaction	hsa04080	Affiliated Target
Class: Environmental Information Processing => Signaling molecules and interaction	Pathway Hierarchy

Degree	2	Degree centrality	2.15E-04	Betweenness centrality	2.02E-04
Closeness centrality	1.66E-01	Radiality	1.25E+01	Clustering coefficient	0.00E+00
Neighborhood connectivity	2.50E+00	Topological coefficient	5.00E-01	Eccentricity	13
Download	Click to Download the Full PPI Network of This Target

Chemical Structure based Activity Landscape of Target

Top

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

Target Poor or Non Binders

Top

Target Poor or Non Binders

Target Poor or Non Binders Info

Target Profiles in Patients

Top

Target Expression
Profile (TEP)

Target Expression Profile Info

Target Affiliated Biological Pathways

Top

KEGG Pathway

[+] 3 KEGG Pathways

Calcium signaling pathway

Neuroactive ligand-receptor interaction

Measles

Panther Pathway

[+] 1 Panther Pathways

CCKR signaling map ST

Reactome

[+] 1 Reactome Pathways

G alpha (q) signalling events

WikiPathways

[+] 6 WikiPathways

SIDS Susceptibility Pathways

Gastrin-CREB signalling pathway via PKC and MAPK

Spinal Cord Injury

Peptide GPCRs

GPCR ligand binding

GPCR downstream signaling

Target-Related Models and Studies

Top

Target Validation

Target Validation Info

References

Top

REF 1

Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46.

REF 2

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 3

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009602)

REF 4

2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.

REF 5

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5749).

REF 6

ClinicalTrials.gov (NCT01500213) A Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy. U.S. National Institutes of Health.

REF 7

REF 8

ClinicalTrials.gov (NCT00640159) Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. U.S. National Institutes of Health.

REF 9

ClinicalTrials.gov (NCT05099159) A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women. U.S.National Institutes of Health.

REF 10

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 11

REF 12

ClinicalTrials.gov (NCT01339260) An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting. U.S. National Institutes of Health.

REF 13

Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther.2012 Feb;35(3):360-7.

REF 14

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007429)

REF 15

Dapitant. RPR 100893. Drugs R D. 1999 Dec;2(6):383-4.

REF 16

REF 17

Acute Endothelin-Receptor Inhibition Does Not Attenuate Acetylcholine-Induced Coronary Vasoconstriction in Experimental Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998.18: 108-113.

REF 18

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015473)

REF 19

REF 20

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006197)

REF 21

ClinicalTrials.gov (NCT00804973) Study in Subjects With Acute Migraines Headaches.. U.S. National Institutes of Health.

REF 22

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020168)

REF 23

Clinical pipeline report, company report or official report of OPKO Health Inc.

REF 24

ClinicalTrials.gov (NCT00174798) MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.. U.S. National Institutes of Health.

REF 25

The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain. 2006 Aug;10(6):567-71.

REF 26

REF 27

ClinicalTrials.gov (NCT00606697) A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia. U.S. National Institutes of Health.

REF 28

HIV ANTIRETROVIRAL DRUG SUSCEPTIBILITY AND DRUG INTERACTIONS (DIRECTOR: MARK MANAK). The Children's Hospital of Philadelphia.

REF 29

ClinicalTrials.gov (NCT02199899) Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers. U.S. National Institutes of Health.

REF 30

ClinicalTrials.gov (NCT01090440) Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects (MNK112891) in GlaxoSmithKline.

REF 31

REF 32

Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.

REF 33

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015961)

REF 34

REF 35

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003930)

REF 36

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004456)

REF 37

Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.

REF 38

REF 39

Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.

REF 40

REF 41

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001455)

REF 42

REF 43

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001953)

REF 44

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021639)

REF 45

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021516)

REF 46

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010524)

REF 47

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014508)

REF 48

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001352)

REF 49

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005872)

REF 50

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009849)

REF 51

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009948)

REF 52

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010564)

REF 53

REF 54

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001969)

REF 55

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005879)

REF 56

Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.

REF 57

Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).

REF 58

Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498.

REF 59

A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.

REF 60

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004225)

REF 61

Application of LC-NMR to the identification of bulk drug impurities in NK1 antagonist GW597599 (vestipitant). Magn Reson Chem. 2010 Jul;48(7):523-30.

REF 62

NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6783-94.

REF 63

REF 64

Clinical pipeline report, company report or official report of OPKO Health, Inc.

REF 65

SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9.

REF 66

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58.

REF 67

Neurokinin-1 receptor, a new modulator of lymphangiogenesis in obese-asthma phenotype. Life Sci. 2013 Aug 6;93(4):169-77.

REF 68

Investigation of figopitant and its metabolites in rat tissue by combining whole-body autoradiography with liquid extraction surface analysis mass spectrometry. Drug Metab Dispos. 2012 Mar;40(3):419-25.

REF 69

Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39.

REF 70

WO patent application no. 2006,0132,05, Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation.

REF 71

The potency of the novel tachykinin receptor antagonist CGP49823 at rat and gerbil motoneurones in vitro. Eur J Pharmacol. 1998 Jan 26;342(2-3):203-8.

REF 72

Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J. 2004 Jan;23(1):76-81.

REF 73

Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. Life Sci. 2009 Aug 12;85(7-8):309-15.

REF 74

Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerv... J Pharmacol Exp Ther. 1992 Jul;262(1):403-8.

REF 75

FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity. J Pharmacol Exp Ther. 1992 Jul;262(1):398-402.

REF 76

[Discovery and pharmacological properties of selective neurokinin-receptor antagonists, FK224 and FK888].Nihon Yakurigaku Zasshi.1995 Sep;106(3):193-204.

REF 77

Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888. Br J Pharmacol. 1992 Nov;107(3):785-9.

REF 78

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021639)

REF 79

The effects of SDZ NKT 343, a potent NK1 receptor antagonist, on cutaneous responses of primate spinothalamic tract neurones sensitized by intradermal capsaicin injection. Exp Brain Res. 1998 Aug;121(3):355-8.

REF 80

Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther. 2002 Nov;303(2):730-5.

REF 81

2-Aryl-1-azabicyclo[2.2.2]octanes as novel nonpeptide substance P antagonists, Bioorg. Med. Chem. Lett. 4(6):839-842 (1994).

REF 82

FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity. Br J Pharmacol. 1992 May;106(1):123-6.

REF 83

Effect of the NK-1 receptor antagonist GR 82,334 on reflexly-induced bladder contractions. Life Sci. 1992;51(26):PL277-80.

REF 84

The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor anta... Bioorg Med Chem. 2009 Oct 15;17(20):7337-43.

REF 85

3-Benzyloxy-2-phenylpiperidine NK1 antagonists: the influence of alpha methyl substitution, Bioorg. Med. Chem. Lett. 7(23):2959-2962 (1997).

REF 86

N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists. J Med Chem. 1996 Jul 19;39(15):2907-14.

REF 87

Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist. Eur J Pharmacol. 1998 Jan 12;341(2-3):201-9.

REF 88

Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets. Br J Pharmacol. 2001 Jan;132(1):189-96.

REF 89

Effects of RP 67580, a tachykinin NK1 receptor antagonist, on a primary afferent-evoked response of ventral roots in the neonatal rat spinal cord. Br J Pharmacol. 1994 Dec;113(4):1141-6.

REF 90

WIN 64821, a novel neurokinin antagonist produced by an Aspergillus sp. II. Biological activity. J Antibiot (Tokyo). 1994 Apr;47(4):399-410.

REF 91

Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9.

REF 92

Spirocyclic NK(1) antagonists II: [4.5]-spiroethers. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2719-22.

REF 93

Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.

REF 94

Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of... J Med Chem. 1998 Oct 22;41(22):4232-9.

REF 95

Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6.

REF 96

Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1362-5.

REF 97

A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.

REF 98

The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7.

REF 99

N-acyl-L-tryptophan benzyl esters: potent substance P receptor antagonists. J Med Chem. 1993 Jul 9;36(14):2044-5.

REF 100

Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.

REF 101

Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther.1997 Jun;281(3):1303-11.

REF 102

Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.

REF 103

Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist. J Pharmacol Exp Ther. 2002 Aug;302(2):696-709.

REF 104

SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol. 2002 Aug 23;450(2):191-202.

REF 105

Septide: an agonist for the NK1 receptor acting at a site distinct from substance P. Mol Pharmacol. 1994 Feb;45(2):287-93.

REF 106

Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4833-5.

REF 107

Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist. Bioorg Med Chem Lett. 1998 Feb 3;8(3):281-4.

REF 108

Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile d... J Pharmacol Sci. 2008 Jan;106(1):121-7.

REF 109

The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47.

REF 110

DOI: 10.1021/jo00074a031

REF 111

WIN 66306, a new neurokinin antagonist produced by an Aspergillus species: fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo). 1994 Nov;47(11):1182-7.

REF 112

Radioiodinated L-703,606: a potent, selective antagonist to the human NK1 receptor. Appl Radiat Isot. 1994 Jan;45(1):97-103.

REF 113

cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.

REF 114

Structures of neurokinin 1 receptor in complex with G(q) and G(s) proteins reveal substance P binding mode and unique activation features. Sci Adv. 2021 Dec 10;7(50):eabk2872.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Yuzong CHEN

Prof. Feng ZHU